Nizatidine Shortage Update: What Patients Need to Know in 2026

If you've been searching for "nizatidine shortage 2026," you're not alone. Many patients who rely on this H2 blocker for GERD, peptic ulcers, and heartburn have encountered pharmacy stock issues. Here's a clear, up-to-date breakdown of nizatidine's availability — including the history of the NDMA recalls that disrupted supply — and what you can do right now.

Is Nizatidine Currently in Shortage? (2026 Update)

As of 2026, nizatidine is not listed on the FDA's official Drug Shortage Database. This means the FDA is not actively tracking a national supply disruption for this medication. Multiple generic manufacturers — including Glenmark, Amneal, Apotex, and Teva — produce nizatidine capsules and supply the U.S. market.

However, "no official shortage" doesn't always translate to easy access at your local pharmacy. Because nizatidine is prescription-only and lower-demand compared to OTC drugs like famotidine, individual pharmacy locations may keep limited stock on hand. A single shipment delay or a temporary spike in local demand can result in a pharmacy being out of stock.

The NDMA Recall: What Happened and Why It Still Affects Supply

To understand why nizatidine can be hard to find in 2026, you need to know about the NDMA (N-nitrosodimethylamine) contamination crisis that began in 2019.

NDMA is a potential carcinogen found in some processed foods and drinking water at low levels. In 2019, FDA testing found that some lots of ranitidine (Zantac) and nizatidine contained NDMA above the FDA's acceptable daily intake limit of 96 nanograms per day. This triggered a cascade of events:

Late 2019: FDA asked manufacturers to test their products; voluntary recalls began for some lots of nizatidine capsules and oral solution

Early 2020: Additional recalls of nizatidine oral solution (Amneal) and capsules (Mylan) due to NDMA above acceptable limits

April 2020: FDA requested withdrawal of all ranitidine (Zantac) from the market. Nizatidine was NOT fully withdrawn, but it was severely impacted

2021 onward: Nizatidine capsules from compliant manufacturers returned to market; availability gradually improved

The recalls had lasting ripple effects. Some insurers and pharmacy chains shifted patients to famotidine or PPIs during the disruption — and many never went back. With lower overall demand for nizatidine, some pharmacies reduced how much they stock, creating localized availability problems even in the absence of a formal shortage.

Who Is Most Affected?

Patients who are most likely to encounter nizatidine stock issues in 2026 include:

Those filling prescriptions at smaller, lower-volume pharmacies in rural or suburban areas

Patients on long-term maintenance doses who need regular monthly refills

Those who switched pharmacies recently and whose new pharmacy doesn't routinely stock it

What Patients Can Do Right Now

Call ahead. Before sending in your prescription, call the pharmacy and ask if they have nizatidine in your dose in stock.

Try different pharmacy chains. Different chains and independent pharmacies use different wholesalers and may have stock when others don't.

Use medfinder.

medfinder calls pharmacies near you to find which ones have your nizatidine prescription in stock, then texts you the results. It saves you the time and frustration of calling around yourself.

Talk to your doctor about options. If nizatidine is genuinely unavailable, famotidine (Pepcid) is the most comparable H2 blocker and is widely available OTC.

Will the Nizatidine Situation Improve?

Yes. Nizatidine's long-term outlook is stable. Multiple compliant manufacturers are producing it, and there's no structural supply problem of the kind that causes prolonged national shortages. The availability issues in 2026 are primarily localized — a specific pharmacy not stocking enough — rather than a system-wide supply failure. For more tips on locating nizatidine near you, see our guide: How to Find Nizatidine in Stock Near You.